{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:24:02Z","timestamp":1787009042507,"version":"build-2736575974"},"reference-count":151,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"National Institute of Child Health & Human Development"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23HD091365"],"award-info":[{"award-number":["K23HD091365"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute of Child Health & Human Development"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1K99HD096123"],"award-info":[{"award-number":["1K99HD096123"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Drug-induced nephrotoxicity is responsible for 20% to 60% of cases of acute kidney injury in hospitalized patients and is associated with increased morbidity and mortality in both children and adults. Antimicrobials are one of the most common classes of medications prescribed globally and also among the most common causes of nephrotoxicity. A broad range of antimicrobial agents have been associated with nephrotoxicity, but the features of kidney injury vary based on the agent, its mechanism of injury and the site of toxicity within the kidney. Distinguishing nephrotoxicity caused by an antimicrobial agent from other potential inciting factors is important to facilitate both early recognition of drug toxicity and prompt cessation of an offending drug, as well as to avoid unnecessary discontinuation of an innocuous therapy. This review will detail the different types of antimicrobial-induced nephrotoxicity: acute tubular necrosis, acute interstitial nephritis and obstructive nephropathy. It will also describe the mechanism of injury caused by specific antimicrobial agents and classes (vancomycin, aminoglycosides, polymyxins, antivirals, amphotericin B), highlight the toxicodynamics of these drugs and provide guidance on administration or monitoring practices that can mitigate toxicity, when known. Particular attention will be paid to paediatric patients, when applicable, in whom nephrotoxin exposure is an often-underappreciated cause of kidney injury.<\/jats:p>","DOI":"10.1093\/jac\/dkz325","type":"journal-article","created":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T08:50:19Z","timestamp":1562403019000},"page":"1-13","source":"Crossref","is-referenced-by-count":78,"title":["Mechanisms of antimicrobial-induced nephrotoxicity in children"],"prefix":"10.1093","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5015-8146","authenticated-orcid":false,"given":"Kevin J","family":"Downes","sequence":"first","affiliation":[{"name":"Department of Pediatrics, The University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA"},{"name":"Division of Infectious Diseases, Children\u2019s Hospital of Philadelphia, Philadelphia, PA, USA"},{"name":"Center for Clinical Pharmacology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA, USA"},{"name":"Center for Pediatric Clinical Effectiveness, Children\u2019s Hospital of Philadelphia, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Hayes","sequence":"additional","affiliation":[{"name":"Antimicrobial Stewardship Program, Center for Healthcare Quality & Analytics, Children\u2019s Hospital of Philadelphia, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie C","family":"Fitzgerald","sequence":"additional","affiliation":[{"name":"Division of Critical Care Medicine, Children\u2019s Hospital of Philadelphia, Philadelphia, PA, USA"},{"name":"Department of Anesthesiology and Critical Care, The University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendolyn M","family":"Pais","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Chicago College of Pharmacy, Midwestern University, Downers Grove, IL, USA"},{"name":"Pharmacometrics Center of Excellence, Chicago College of Pharmacy, Midwestern University, Downers Grove, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Chicago College of Pharmacy, Midwestern University, Downers Grove, IL, USA"},{"name":"Pharmacometrics Center of Excellence, Chicago College of Pharmacy, Midwestern University, Downers Grove, IL, USA"},{"name":"Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R","family":"Zane","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart L","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA"},{"name":"Center for Acute Care Nephrology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1091-6130","authenticated-orcid":false,"given":"Marc H","family":"Scheetz","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Chicago College of Pharmacy, Midwestern University, Downers Grove, IL, USA"},{"name":"Pharmacometrics Center of Excellence, Chicago College of Pharmacy, Midwestern University, Downers Grove, IL, USA"},{"name":"Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, USA"},{"name":"Department of Pharmacology, College of Graduate Studies, Midwestern University, Downers Grove, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athena F","family":"Zuppa","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA, USA"},{"name":"Division of Critical Care Medicine, Children\u2019s Hospital of Philadelphia, Philadelphia, PA, USA"},{"name":"Department of Anesthesiology and Critical Care, The University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,1]]},"reference":[{"key":"2019121310373667400_dkz325-B1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0272-2712(18)30459-1","article-title":"Assessment of renal function\u2013glomerular and tubular","volume":"13","author":"Duarte","year":"1993","journal-title":"Clin Lab Med"},{"key":"2019121310373667400_dkz325-B2","doi-asserted-by":"crossref","first-page":"856","DOI":"10.2215\/CJN.08110910","article-title":"Acute kidney injury and increasing nephrotoxic-medication exposure in noncritically-ill children","volume":"6","author":"Moffett","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019121310373667400_dkz325-B3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40272-016-0205-1","article-title":"Identifying high-risk medications associated with acute kidney injury in critically ill patients: a pharmacoepidemiologic evaluation","volume":"19","author":"Slater","year":"2017","journal-title":"Paediatr Drugs"},{"key":"2019121310373667400_dkz325-B4","first-page":"871","article-title":"Antibiotics induced acute kidney injury: incidence, risk factors, onset time and outcome","volume":"51","author":"Khalili","year":"2013","journal-title":"Acta Med Iran"},{"key":"2019121310373667400_dkz325-B5","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1517\/14740330802410462","article-title":"The epidemiology of drug-induced disorders: the kidney","volume":"7","author":"Taber","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"2019121310373667400_dkz325-B6","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1111\/j.1523-1755.2004.00927.x","article-title":"Spectrum of acute renal failure in the intensive care unit: the PICARD experience","volume":"66","author":"Mehta","year":"2004","journal-title":"Kidney Int"},{"key":"2019121310373667400_dkz325-B7","doi-asserted-by":"crossref","first-page":"e756","DOI":"10.1542\/peds.2013-0794","article-title":"Electronic health record identification of nephrotoxin exposure and associated acute kidney injury","volume":"132","author":"Goldstein","year":"2013","journal-title":"Pediatrics"},{"key":"2019121310373667400_dkz325-B8","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1093\/jac\/dkv418","article-title":"The Worldwide Antibiotic Resistance and Prescribing in European Children (ARPEC) point prevalence survey: developing hospital-quality indicators of antibiotic prescribing for children","volume":"71","author":"Versporten","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2019121310373667400_dkz325-B9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/ncpneph0076","article-title":"Drug-associated renal dysfunction and injury","volume":"2","author":"Choudhury","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"key":"2019121310373667400_dkz325-B10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-3-642-00663-0_5","article-title":"Mechanisms of drug-induced nephrotoxicity","volume":"196","author":"Nolin","year":"2010","journal-title":"Handb Exp Pharmacol"},{"key":"2019121310373667400_dkz325-B11","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1055\/s-0033-1361933","article-title":"Medication use in the neonatal intensive care unit","volume":"31","author":"Hsieh","year":"2014","journal-title":"Am J Perinatol"},{"key":"2019121310373667400_dkz325-B12","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/ki.2015.115","article-title":"Phenotype standardization for drug-induced kidney disease","volume":"88","author":"Mehta","year":"2015","journal-title":"Kidney Int"},{"key":"2019121310373667400_dkz325-B13","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1097\/CCM.0b013e318168e375","article-title":"An overview of drug-induced acute kidney injury","volume":"36 Suppl 4","author":"Pannu","year":"2008","journal-title":"Crit Care Med"},{"key":"2019121310373667400_dkz325-B14","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1208\/s12248-011-9301-x","article-title":"Biomarkers for drug-induced renal damage and nephrotoxicity\u2014an overview for applied toxicology","volume":"13","author":"Fuchs","year":"2011","journal-title":"AAPS J"},{"key":"2019121310373667400_dkz325-B15","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/jcp.2008.058271","article-title":"Renal toxicity of therapeutic drugs","volume":"62","author":"John","year":"2009","journal-title":"J Clin Pathol"},{"key":"2019121310373667400_dkz325-B16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cccn.2004.09.005","article-title":"Drug-induced renal failure: a focus on tubulointerstitial disease","volume":"351","author":"Markowitz","year":"2005","journal-title":"Clin Chim Acta"},{"key":"2019121310373667400_dkz325-B17","first-page":"138","article-title":"The rise and fall of acute tubular necrosis - an exercise in medical semiotics","volume":"35","author":"George","year":"2018","journal-title":"G Ital Nefrol"},{"key":"2019121310373667400_dkz325-B18","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ki.1983.162","article-title":"Role of tubular obstruction in acute renal failure due to gentamicin","volume":"24","author":"Neugarten","year":"1983","journal-title":"Kidney Int"},{"key":"2019121310373667400_dkz325-B19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/ki.2010.337","article-title":"New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view","volume":"79","author":"Lopez-Novoa","year":"2011","journal-title":"Kidney Int"},{"key":"2019121310373667400_dkz325-B20","first-page":"169","article-title":"Tubuloglomerular feedback and the control of glomerular filtration rate","volume":"18","author":"Vallon","year":"2003","journal-title":"News Physiol Sci"},{"key":"2019121310373667400_dkz325-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2015.12.001","article-title":"Adverse effects of drugs on the kidney","volume":"28","author":"Bartoli","year":"2016","journal-title":"Eur J Intern Med"},{"key":"2019121310373667400_dkz325-B22","first-page":"3","article-title":"Drug-induced acute interstitial nephritis: pathology, pathogenesis, and treatment","volume":"9","author":"Krishnan","year":"2015","journal-title":"Iran J Kidney Dis"},{"key":"2019121310373667400_dkz325-B23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/ndt\/gfg464","article-title":"The changing profile of acute tubulointerstitial nephritis","volume":"19","author":"Baker","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"2019121310373667400_dkz325-B24","doi-asserted-by":"crossref","first-page":"381","DOI":"10.5414\/CN108301","article-title":"Diagnosing drug-induced AIN in the hospitalized patient: a challenge for the clinician","volume":"81","author":"Perazella","year":"2014","journal-title":"Clin Nephrol"},{"key":"2019121310373667400_dkz325-B25","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2215\/CJN.01330213","article-title":"Utility of urine eosinophils in the diagnosis of acute interstitial nephritis","volume":"8","author":"Muriithi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019121310373667400_dkz325-B26","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.2215\/CJN.07630717","article-title":"Drug-induced acute interstitial nephritis","volume":"12","author":"Moledina","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019121310373667400_dkz325-B27","first-page":"57","article-title":"Drug-induced renal disorders","volume":"4","author":"Ghane Shahrbaf","year":"2015","journal-title":"J Renal Inj Prev"},{"key":"2019121310373667400_dkz325-B28","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrneph.2017.10","article-title":"Crystal nephropathies: mechanisms of crystal-induced kidney injury","volume":"13","author":"Mulay","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2019121310373667400_dkz325-B29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000487671","article-title":"Novel insights into crystal-induced kidney injury","volume":"4","author":"Mulay","year":"2018","journal-title":"Kidney Dis (Basel)"},{"key":"2019121310373667400_dkz325-B30","doi-asserted-by":"crossref","first-page":"602783.","DOI":"10.1155\/2010\/602783","article-title":"Acyclovir nephrotoxicity: a case report highlighting the importance of prevention, detection, and treatment of acyclovir-induced nephropathy","volume":"2010","author":"Fleischer","year":"2010","journal-title":"Case Rep Med"},{"key":"2019121310373667400_dkz325-B31","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrneph.2009.142","article-title":"The nephrotoxic effects of HAART","volume":"5","author":"Izzedine","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"2019121310373667400_dkz325-B32","doi-asserted-by":"crossref","first-page":"E23.","DOI":"10.1053\/ajkd.2001.27732","article-title":"Indinavir nephropathy revisited: a pattern of insidious renal failure with identifiable risk factors","volume":"38","author":"Reilly","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"2019121310373667400_dkz325-B33","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1053\/j.ajkd.2007.05.014","article-title":"Ciprofloxacin crystal nephropathy","volume":"50","author":"Stratta","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"2019121310373667400_dkz325-B34","first-page":"29","article-title":"Crystal-induced acute kidney injury due to ciprofloxacin","volume":"4","author":"Khan","year":"2015","journal-title":"J Nephropathol"},{"key":"2019121310373667400_dkz325-B35","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4103\/0971-4065.200522","article-title":"Acute ciprofloxacin-induced crystal nephropathy with granulomatous interstitial nephritis","volume":"27","author":"Goli","year":"2017","journal-title":"Indian J Nephrol"},{"key":"2019121310373667400_dkz325-B36","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1086\/491709","article-title":"Vancomycin: a history","volume":"42 Suppl 1","author":"Levine","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2019121310373667400_dkz325-B37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jac\/14.suppl_D.7","article-title":"Mode of action and in-vitro activity of vancomycin","volume":"14 Suppl D","author":"Watanakunakorn","year":"1984","journal-title":"J Antimicrob Chemother"},{"key":"2019121310373667400_dkz325-B38","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1093\/cid\/cit614","article-title":"Methicillin-resistant Staphylococcus aureus therapy: past, present, and future","volume":"58 Suppl 1","author":"Rodvold","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2019121310373667400_dkz325-B39","first-page":"694","article-title":"The use of vancomycin with its therapeutic and adverse effects: a review","volume":"19","author":"Bruniera","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2019121310373667400_dkz325-B40","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/INF.0000000000001882","article-title":"Nephrotoxicity with vancomycin in the pediatric population: a systematic review and meta-analysis","volume":"37","author":"Fiorito","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"2019121310373667400_dkz325-B41","doi-asserted-by":"crossref","first-page":"436856.","DOI":"10.4061\/2011\/436856","article-title":"Biopsy-proven acute tubular necrosis due to vancomycin toxicity","volume":"2011","author":"Shah-Khan","year":"2011","journal-title":"Int J Nephrol"},{"key":"2019121310373667400_dkz325-B42","doi-asserted-by":"crossref","first-page":"72.","DOI":"10.1186\/s12882-018-0845-1","article-title":"Biopsy-proven vancomycin-induced acute kidney injury: a case report and literature review","volume":"19","author":"Sawada","year":"2018","journal-title":"BMC Nephrol"},{"key":"2019121310373667400_dkz325-B43","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1001\/archinte.1988.00380100037008","article-title":"Acute interstitial nephritis associated with vancomycin therapy","volume":"148","author":"Bergman","year":"1988","journal-title":"Arch Intern Med"},{"key":"2019121310373667400_dkz325-B44","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1007\/s00467-006-0152-0","article-title":"Biopsy-proven acute tubular necrosis in a child attributed to vancomycin intoxication","volume":"21","author":"Wicklow","year":"2006","journal-title":"Pediatr Nephrol"},{"key":"2019121310373667400_dkz325-B45","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1080\/08860220701643773","article-title":"Biopsy proven acute tubular necrosis associated with vancomycin in a child: case report and literature review","volume":"29","author":"Wu","year":"2007","journal-title":"Ren Fail"},{"key":"2019121310373667400_dkz325-B46","first-page":"678724.","article-title":"Successful utilization of high-flux hemodialysis for treatment of vancomycin toxicity in a child","volume":"2011","author":"Stidham","year":"2011","journal-title":"Case Rep Pediatr"},{"key":"2019121310373667400_dkz325-B47","first-page":"327","article-title":"[Acute interstitial nephropathy induced by vancomycin]","volume":"17","author":"Azar","year":"1996","journal-title":"Nephrologie"},{"key":"2019121310373667400_dkz325-B48","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1681\/ASN.2016080867","article-title":"Vancomycin-associated cast nephropathy","volume":"28","author":"Luque","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2019121310373667400_dkz325-B49","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.freeradbiomed.2012.02.038","article-title":"Mitochondrial superoxide production contributes to vancomycin-induced renal tubular cell apoptosis","volume":"52","author":"Arimura","year":"2012","journal-title":"Free Radic Biol Med"},{"key":"2019121310373667400_dkz325-B50","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.tiv.2004.03.013","article-title":"Proliferative responses observed following vancomycin treatment in renal proximal tubule epithelial cells","volume":"18","author":"King","year":"2004","journal-title":"Toxicol In Vitro"},{"key":"2019121310373667400_dkz325-B51","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/1071576031000061002","article-title":"Targeting superoxide dismutase to renal proximal tubule cells attenuates vancomycin-induced nephrotoxicity in rats","volume":"37","author":"Nishino","year":"2003","journal-title":"Free Radic Res"},{"key":"2019121310373667400_dkz325-B52","doi-asserted-by":"crossref","first-page":"704382.","DOI":"10.1155\/2015\/704382","article-title":"Protective effects of cilastatin against vancomycin-induced nephrotoxicity","volume":"2015","author":"Humanes","year":"2015","journal-title":"Biomed Res Int"},{"key":"2019121310373667400_dkz325-B53","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1681\/ASN.2016060606","article-title":"Megalin blockade with cilastatin suppresses drug-induced nephrotoxicity","volume":"28","author":"Hori","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2019121310373667400_dkz325-B54","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2019121310373667400_dkz325-B55","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2019121310373667400_dkz325-B56","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1128\/AAC.00173-11","article-title":"Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients","volume":"55","author":"Minejima","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2019121310373667400_dkz325-B57","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2019121310373667400_dkz325-B58","first-page":"e00416","article-title":"24-Hour pharmacokinetic relationships for vancomycin and novel urinary biomarkers of acute kidney injury","volume":"61","author":"O\u2019Donnell","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019121310373667400_dkz325-B59","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1128\/AAC.00591-16","article-title":"Evaluation of vancomycin exposures associated with elevations in novel urinary biomarkers of acute kidney injury in vancomycin-treated rats","volume":"60","author":"Rhodes","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019121310373667400_dkz325-B60","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciz051","article-title":"Vancomycin area under the curve and acute kidney injury: a meta-analysis","author":"Aljefri","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2019121310373667400_dkz325-B61","doi-asserted-by":"crossref","first-page":"e02042","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019121310373667400_dkz325-B62","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1093\/jpids\/piu110","article-title":"Pharmacodynamic characteristics of nephrotoxicity associated with vancomycin use in children","volume":"4","author":"Le","year":"2015","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2019121310373667400_dkz325-B63","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1093\/ofid\/ofx162.074","article-title":"The Emperor\u2019s New Clothes: prospective observational evaluation of the association between the day 2 vancomycin exposure and failure rates among adult hospitalized patients with MRSA bloodstream infections (PROVIDE)","volume":"4 Suppl 1","author":"Lodise","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2019121310373667400_dkz325-B64","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1093\/cid\/ciy680","article-title":"A prospective multicenter clinical observational study on vancomycin efficiency and safety with therapeutic drug monitoring","volume":"67 Suppl 2","author":"Liang","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2019121310373667400_dkz325-B65","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40272-015-0117-5","article-title":"Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC\/MIC?","volume":"17","author":"Patel","year":"2015","journal-title":"Paediatr Drugs"},{"key":"2019121310373667400_dkz325-B66","first-page":"406","article-title":"Vancomycin dosing and monitoring in the treatment of cystic fibrosis: results of a national practice survey","volume":"22","author":"Pettit","year":"2017","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2019121310373667400_dkz325-B67","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/INF.0000000000000243","article-title":"Neonatal vancomycin continuous infusion: still a confusion?","volume":"33","author":"Gwee","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2019121310373667400_dkz325-B68","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00467-016-3533-z","article-title":"Aminoglycoside-induced nephrotoxicity in children","volume":"32","author":"McWilliam","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"2019121310373667400_dkz325-B69","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0025-6196(11)65134-3","article-title":"The aminoglycosides","volume":"74","author":"Edson","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"2019121310373667400_dkz325-B70","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2174\/1568005043340858","article-title":"Aminoglycoside nephrotoxicity","volume":"4","author":"Rougier","year":"2004","journal-title":"Curr Drug Targets Infect Disord"},{"key":"2019121310373667400_dkz325-B71","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1172\/JCI118176","article-title":"Evidence that epithelial glycoprotein 330\/megalin mediates uptake of polybasic drugs","volume":"96","author":"Moestrup","year":"1995","journal-title":"J Clin Invest"},{"key":"2019121310373667400_dkz325-B72","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1074\/jbc.M109959200","article-title":"Megalin deficiency offers protection from renal aminoglycoside accumulation","volume":"277","author":"Schmitz","year":"2002","journal-title":"J Biol Chem"},{"key":"2019121310373667400_dkz325-B73","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/ki.1979.45","article-title":"Autoradiography of gentamicin uptake by the rat proximal tubule cell","volume":"15","author":"Silverblatt","year":"1979","journal-title":"Kidney Int"},{"key":"2019121310373667400_dkz325-B74","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.taap.2004.11.024","article-title":"Gentamicin-induced apoptosis in LLC-PK1 cells: involvement of lysosomes and mitochondria","volume":"206","author":"Servais","year":"2005","journal-title":"Toxicol Appl Pharmacol"},{"key":"2019121310373667400_dkz325-B75","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/ki.1984.69","article-title":"Early effects of gentamicin, tobramycin, and amikacin on the human kidney","volume":"25","author":"De Broe","year":"1984","journal-title":"Kidney Int"},{"key":"2019121310373667400_dkz325-B76","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.lfs.2007.11.014","article-title":"Time dependent effects of gentamicin on the enzymes of carbohydrate metabolism, brush border membrane and oxidative stress in rat kidney tissues","volume":"82","author":"Banday","year":"2008","journal-title":"Life Sci"},{"key":"2019121310373667400_dkz325-B77","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/INF.0b013e31820f0f3a","article-title":"Extended-interval aminoglycoside dosing in pediatrics","volume":"30","author":"Jenh","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"2019121310373667400_dkz325-B78","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1128\/AAC.39.3.650","article-title":"Experience with a once-daily aminoglycoside program administered to 2,184 adult patients","volume":"39","author":"Nicolau","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"2019121310373667400_dkz325-B79","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/jac\/25.1.159","article-title":"Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity?","volume":"25","author":"Nordstrom","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"2019121310373667400_dkz325-B80","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0140-6736(93)90137-6","article-title":"Once versus thrice daily gentamicin in patients with serious infections","volume":"341","author":"Prins","year":"1993","journal-title":"Lancet"},{"key":"2019121310373667400_dkz325-B81","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1128\/AAC.35.3.399","article-title":"Once-daily aminoglycoside therapy","volume":"35","author":"Gilbert","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"2019121310373667400_dkz325-B82","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1542\/peds.114.1.e111","article-title":"Extended-interval aminoglycoside administration for children: a meta-analysis","volume":"114","author":"Contopoulos-Ioannidis","year":"2004","journal-title":"Pediatrics"},{"key":"2019121310373667400_dkz325-B83","doi-asserted-by":"crossref","first-page":"288.","DOI":"10.1186\/1471-2334-14-288","article-title":"How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?","volume":"14","author":"Wong","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2019121310373667400_dkz325-B84","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jcf.2006.05.015","article-title":"Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis\u2014caution with trough concentrations","volume":"6","author":"Coulthard","year":"2007","journal-title":"J Cyst Fibros"},{"key":"2019121310373667400_dkz325-B85","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1469-0691.2011.03734.x","article-title":"Colistin: new lessons on an old antibiotic","volume":"18","author":"Yahav","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2019121310373667400_dkz325-B86","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1086\/429323","article-title":"Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections","volume":"40","author":"Falagas","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2019121310373667400_dkz325-B87","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-72-6-857","article-title":"Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy","volume":"72","author":"Koch-Weser","year":"1970","journal-title":"Ann Intern Med"},{"key":"2019121310373667400_dkz325-B88","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/INF.0b013e3182703790","article-title":"The use of intravenous colistin among children in the United States: results from a multicenter, case series","volume":"32","author":"Tamma","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"2019121310373667400_dkz325-B89","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1345\/aph.18426","article-title":"Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria","volume":"33","author":"Evans","year":"1999","journal-title":"Ann Pharmacother"},{"key":"2019121310373667400_dkz325-B90","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/FTD.0b013e31825c827a","article-title":"High performance liquid chromatography-mass spectrometry assay for polymyxin B1 and B2 in human plasma","volume":"34","author":"Thomas","year":"2012","journal-title":"Ther Drug Monit"},{"key":"2019121310373667400_dkz325-B91","first-page":"87","volume-title":"Casebook in Clinical Pharmacokinetics and Drug Dosing","author":"Voigt","year":"2015"},{"key":"2019121310373667400_dkz325-B92","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s13312-015-0586-1","article-title":"Safety and efficacy of intravenous colistin in children","volume":"52","author":"Kumar","year":"2015","journal-title":"Indian Pediatr"},{"key":"2019121310373667400_dkz325-B93","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1097\/INF.0000000000000117","article-title":"The use of colistin in critically ill children in a pediatric intensive care unit","volume":"33","author":"Karbuz","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2019121310373667400_dkz325-B94","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/INF.0000000000001655","article-title":"Colistin use in neonates and children with infections due to carbapenem-resistant bacteria","volume":"36","author":"Antachopoulos","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"2019121310373667400_dkz325-B95","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/jac\/dkm357","article-title":"Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review","volume":"60","author":"Zavascki","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2019121310373667400_dkz325-B96","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00431-009-1137-3","article-title":"Colistin administration to pediatric and neonatal patients","volume":"169","author":"Iosifidis","year":"2010","journal-title":"Eur J Pediatr"},{"key":"2019121310373667400_dkz325-B97","doi-asserted-by":"crossref","first-page":"e268","DOI":"10.1097\/PCC.0b013e31828a740f","article-title":"Intravenous colistin for multidrug-resistant gram-negative infections in critically ill pediatric patients","volume":"14","author":"Kapoor","year":"2013","journal-title":"Pediatr Crit Care Med"},{"key":"2019121310373667400_dkz325-B98","doi-asserted-by":"crossref","first-page":"503.e501","DOI":"10.1016\/j.ijantimicag.2008.10.021","article-title":"Systemic colistin use in children without cystic fibrosis: a systematic review of the literature","volume":"33","author":"Falagas","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"2019121310373667400_dkz325-B99","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/phar.1493","article-title":"Adverse reactions associated with systemic polymyxin therapy","volume":"35","author":"Justo","year":"2015","journal-title":"Pharmacotherapy"},{"key":"2019121310373667400_dkz325-B100","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1517\/14740338.2015.1088520","article-title":"The safety of polymyxin antibiotics","volume":"14","author":"Kelesidis","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"2019121310373667400_dkz325-B101","doi-asserted-by":"crossref","first-page":"e0161057.","DOI":"10.1371\/journal.pone.0161057","article-title":"Polymyxin B nephrotoxicity: from organ to cell damage","volume":"11","author":"Vattimo Mde","year":"2016","journal-title":"PLoS One"},{"key":"2019121310373667400_dkz325-B102","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.1128\/AAC.00254-13","article-title":"Megalin contributes to kidney accumulation and nephrotoxicity of colistin","volume":"57","author":"Suzuki","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2019121310373667400_dkz325-B103","doi-asserted-by":"crossref","first-page":"e02319","DOI":"10.1128\/AAC.02319-16","article-title":"Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B?","volume":"61","author":"Zavascki","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019121310373667400_dkz325-B104","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/jac\/dkr483","article-title":"Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics","volume":"67","author":"Yousef","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2019121310373667400_dkz325-B105","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1128\/AAC.00328-11","article-title":"Melatonin attenuates colistin-induced nephrotoxicity in rats","volume":"55","author":"Yousef","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2019121310373667400_dkz325-B106","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1128\/AAC.00280-12","article-title":"Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design","volume":"56","author":"Abdelraouf","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2019121310373667400_dkz325-B107","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/cid\/ciu213","article-title":"Colistin and polymyxin B: peas in a pod, or chalk and cheese?","volume":"59","author":"Nation","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2019121310373667400_dkz325-B108","year":"2017"},{"key":"2019121310373667400_dkz325-B109","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1055\/s-0034-1398390","article-title":"Colistin: how should it be dosed for the critically ill?","volume":"36","author":"Landersdorfer","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"2019121310373667400_dkz325-B110","doi-asserted-by":"crossref","first-page":"e01475","DOI":"10.1128\/AAC.01475-17","article-title":"Population pharmacokinetics of polymyxin B in acutely ill adult patients","volume":"62","author":"Miglis","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019121310373667400_dkz325-B111","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/cid\/cit334","article-title":"Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens","volume":"57","author":"Sandri","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2019121310373667400_dkz325-B112","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/j.1875-9114.1983.tb03274.x","article-title":"Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications","volume":"3","author":"Gnann","year":"1983","journal-title":"Pharmacotherapy"},{"key":"2019121310373667400_dkz325-B113","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jpeds.2015.01.023","article-title":"Intravenous acyclovir and renal dysfunction in children: a matched case control study","volume":"166","author":"Rao","year":"2015","journal-title":"J Pediatr"},{"key":"2019121310373667400_dkz325-B114","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1053\/j.ajkd.2005.02.010","article-title":"Antiviral drug-induced nephrotoxicity","volume":"45","author":"Izzedine","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"2019121310373667400_dkz325-B115","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.etap.2016.07.018","article-title":"A metabolic profiling analysis of the nephrotoxicity of acyclovir in rats using ultra performance liquid chromatography\/mass spectrometry","volume":"46","author":"Xing","year":"2016","journal-title":"Environ Toxicol Pharmacol"},{"key":"2019121310373667400_dkz325-B116","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.trsl.2011.07.002","article-title":"Acyclovir-induced nephrotoxicity: the role of the acyclovir aldehyde metabolite","volume":"158","author":"Gunness","year":"2011","journal-title":"Transl Res"},{"key":"2019121310373667400_dkz325-B117","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/BF00856544","article-title":"Reversible renal failure in renal transplant patients receiving oral acyclovir prophylaxis","volume":"8","author":"Ahmad","year":"1994","journal-title":"Pediatr Nephrol"},{"key":"2019121310373667400_dkz325-B118","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00467-002-0867-5","article-title":"Combination of ceftriaxone and acyclovir\u2014an underestimated nephrotoxic potential?","volume":"17","author":"Vomiero","year":"2002","journal-title":"Pediatr Nephrol"},{"key":"2019121310373667400_dkz325-B119","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/petr.12483","article-title":"A systematic review of acute kidney injury in pediatric allogeneic hematopoietic stem cell recipients","volume":"19","author":"Didsbury","year":"2015","journal-title":"Pediatr Transplant"},{"key":"2019121310373667400_dkz325-B120","doi-asserted-by":"crossref","first-page":"8S","DOI":"10.1016\/0002-9343(92)90330-E","article-title":"Clinical pharmacology: foscarnet","volume":"92","author":"Lietman","year":"1992","journal-title":"Am J Med"},{"key":"2019121310373667400_dkz325-B121","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2165\/00002018-199716040-00003","article-title":"Minimising the dosage-limiting toxicities of foscarnet induction therapy","volume":"16","author":"Jayaweera","year":"1997","journal-title":"Drug Saf"},{"key":"2019121310373667400_dkz325-B122","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1365-2559.1999.00642.x","article-title":"Irreversible glomerular lesions induced by crystal precipitation in a renal transplant after foscarnet therapy for cytomegalovirus infection","volume":"34","author":"Justrabo","year":"1999","journal-title":"Histopathology"},{"key":"2019121310373667400_dkz325-B123","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1258\/0956462001914995","article-title":"Safety of oral versus intravenous hydration during induction therapy with intravenous foscarnet in AIDS patients with cytomegalovirus infections","volume":"11","author":"Cheung","year":"2000","journal-title":"Int J STD AIDS"},{"key":"2019121310373667400_dkz325-B124","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0021-9258(18)96249-6","article-title":"The action of polyene antibiotics on phospholipid-cholesterol structures","volume":"242","author":"Weissmann","year":"1967","journal-title":"J Biol Chem"},{"key":"2019121310373667400_dkz325-B125","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1086\/376634","article-title":"Amphotericin B: time for a new \u201cgold standard\u201d","volume":"37","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2019121310373667400_dkz325-B126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1470-9465.2004.00841.x","article-title":"History of the development of azole derivatives","volume":"10 Suppl 1","author":"Maertens","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"2019121310373667400_dkz325-B127","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"2019121310373667400_dkz325-B128","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.idc.2015.10.012","article-title":"Antifungal agents: spectrum of activity, pharmacology, and clinical indications","volume":"30","author":"Nett","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"2019121310373667400_dkz325-B129","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1001\/archinte.1988.00380110049010","article-title":"Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation","volume":"148","author":"Branch","year":"1988","journal-title":"Arch Intern Med"},{"key":"2019121310373667400_dkz325-B130","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM198001173020304","article-title":"Strategies in the treatment of systemic fungal infections","volume":"302","author":"Medoff","year":"1980","journal-title":"N Engl J Med"},{"key":"2019121310373667400_dkz325-B131","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1021\/acs.molpharmaceut.8b00572","article-title":"Mechanism of binding of antifungal antibiotic amphotericin B to lipid membranes: an insight from combined single-membrane imaging, microspectroscopy, and molecular dynamics","volume":"15","author":"Grela","year":"2018","journal-title":"Mol Pharm"},{"key":"2019121310373667400_dkz325-B132","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1128\/AAC.35.12.2509","article-title":"Mechanisms of amphotericin B-induced decrease in glomerular filtration rate in rats","volume":"35","author":"Sabra","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"2019121310373667400_dkz325-B133","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1172\/JCI115240","article-title":"Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats","volume":"87","author":"Sawaya","year":"1991","journal-title":"J Clin Invest"},{"key":"2019121310373667400_dkz325-B134","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1681\/ASN.V62154","article-title":"Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties","volume":"6","author":"Sawaya","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"2019121310373667400_dkz325-B135","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1517\/14740338.2012.721775","article-title":"Are salt loading and prolonging infusion period effective in prevention of amphotericin B-induced nephrotoxicity?","volume":"11","author":"Karimzadeh","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"2019121310373667400_dkz325-B136","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1128\/AAC.45.3.679-685.2001","article-title":"Apoptosis contributes to amphotericin B-induced nephrotoxicity","volume":"45","author":"Varlam","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2019121310373667400_dkz325-B137","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/ki.1977.39","article-title":"Acidifying defect induced by amphotericin B: comparison of bicarbonate and hydrogen ion permeabilities","volume":"11","author":"Finn","year":"1977","journal-title":"Kidney Int"},{"key":"2019121310373667400_dkz325-B138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ki.1981.1","article-title":"Pathogenesis of distal renal tubular acidosis","volume":"19","author":"Stinebaugh","year":"1981","journal-title":"Kidney Int"},{"key":"2019121310373667400_dkz325-B139","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1067\/mlc.2001.117826","article-title":"Amphotericin B decreases adenylyl cyclase activity and aquaporin-2 expression in rat kidney","volume":"138","author":"Kim","year":"2001","journal-title":"J Lab Clin Med"},{"key":"2019121310373667400_dkz325-B140","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1093\/clinids\/22.Supplement_2.S133","article-title":"Lipid formulations of amphotericin B: recent progress and future directions","volume":"22 Suppl 2","author":"Hiemenz","year":"1996","journal-title":"Clin Infect Dis"},{"key":"2019121310373667400_dkz325-B141","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000239202","article-title":"Phagocyte transport as mechanism for enhanced therapeutic activity of liposomal amphotericin B","volume":"40","author":"Mehta","year":"1994","journal-title":"Chemotherapy"},{"key":"2019121310373667400_dkz325-B142","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1128\/AAC.31.3.421","article-title":"Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B","volume":"31","author":"Szoka","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"2019121310373667400_dkz325-B143","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1038\/ki.1992.229","article-title":"Direct amphotericin B-mediated tubular toxicity: assessments of selected cytoprotective agents","volume":"41","author":"Zager","year":"1992","journal-title":"Kidney Int"},{"key":"2019121310373667400_dkz325-B144","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s00228-013-1472-1","article-title":"Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity","volume":"69","author":"Karimzadeh","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"2019121310373667400_dkz325-B145","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/0005-2736(84)90135-4","article-title":"Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells","volume":"770","author":"Mehta","year":"1984","journal-title":"Biochim Biophys Acta"},{"key":"2019121310373667400_dkz325-B146","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/AAC.38.2.223","article-title":"Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B","volume":"38","author":"Wasan","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"2019121310373667400_dkz325-B147","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/myc.12585","article-title":"Efficacy and safety of amphotericin B lipid-based formulations\u2014a systematic review and meta-analysis","volume":"60","author":"Steimbach","year":"2017","journal-title":"Mycoses"},{"key":"2019121310373667400_dkz325-B148","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/jac\/dkh403","article-title":"Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients","volume":"54","author":"Peleg","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"2019121310373667400_dkz325-B149","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1097\/INF.0000000000000299","article-title":"Deoxycholate amphotericin B and nephrotoxicity in the pediatric setting","volume":"33","author":"Bes","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2019121310373667400_dkz325-B150","year":"2017"},{"key":"2019121310373667400_dkz325-B151"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/1\/1\/31512857\/dkz325.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/1\/1\/31512857\/dkz325.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T22:08:01Z","timestamp":1663884481000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/1\/1\/5542610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":151,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,8,1]]},"published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz325","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,1]]},"published":{"date-parts":[[2019,8,1]]}}}